Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04215536 · ClinicalTrials.gov registry record
Replication of the EMPAREG Diabetes Trial in Healthcare Claims
A clinical trial of Diabetes, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 103,752
- Enrollment target
- 1
- Study location
NCT04215536: Completed study of Diabetes, sponsored by Brigham and Women's Hospital.
NCT04215536 is a study of Diabetes that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 103,752 participants, above the 2,721-participant average among 338 other Diabetes trials with a reported enrollment target (3713% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04215536, a study of Diabetes, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 103,752 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Composite outcome of MI, stroke, and mortality - Please refer to uploaded protocol for full definition due to size limitations.
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG DPP-4 inhibitor
Study Locations (1)
Massachusetts
- Brigham & Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103,752 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2021-02-18 |
What the finished NCT04215536 record still lists
NCT04215536 is an observational study that tracks outcomes without assigning an intervention. Its 103,752 participants enrollment target places it among the larger protocols in the corpus, above the 2,721-participant average among 338 other Diabetes trials with a reported enrollment target (3713% higher).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin is the first listed.
NCT04215536 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04215536 about?
NCT04215536 is a clinical study titled "Replication of the EMPAREG Diabetes Trial in Healthcare Claims". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT04215536?
This trial is currently completed. The enrollment target is 103,752 participants. The study started on 2019-07-08. Estimated completion is 2021-02-18.
What conditions does trial NCT04215536 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT04215536?
The interventions under investigation include: Empagliflozin (DRUG), DPP-4 inhibitor (DRUG).
Who is sponsoring clinical trial NCT04215536?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04215536 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04215536's enrollment target sits among peer trials
103,752 3rd of 338 higher than 336 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
RECRUITING
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Taste Bud-Derived Stem Cells in Humans
RECRUITING
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05804188 · 105,000 participants
CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
- NCT02917460 · 102,000 participants · NA
Rady Children's Institute Genomic Biorepository
- NCT05741112 · 100,500 participants · NA
The Long COVID-19 Wearable Device Study
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI